Table 1 Patient characteristics stratified by EGFR testing

Erlotinib use

 No

1096 (85.9%)

872 (80.3%)

 Yes

180 (14.1%)

214 (19.7%)

Afatinib use

 No

1256 (98.4%)

1064 (98.0%)

 Yes

20 (1.6%)

22 (2.0%)

Year of diagnosis

 2013

496 (62.1%)

303 (37.9%)

 2014

379 (48.9%)

396 (51.1%)

2015

401 (50.9%)

387 (49.1%)

Age at diagnosis

 66–69

340 (55.9%)

268 (44.1%)

 70–74

353 (53.7%)

304 (46.3%)

 75–79

303 (53.3%)

265 (46.7%)

  ≥ 80

280 (52.9%)

249 (47.1%)

Sex

 Male

515 (55.0%)

422 (45.0%)

 Female

761 (53.4%)

664 (46.6%)

Race

 White

1003 (53.0%)

891 (47.0%)

 Black

128 (63.4%)

74 (36.6%)

 Asian

73 (51.0%)

70 (49.0%)

 Other (including unknown)

72 (58.5%)

51 (41.5%)

Ethnicity

 Non-Hispanic

1198 (53.7%)

1034 (46.3%)

 Hispanic

78 (60.0%)

52 (40.0%)

Marital status

 Not married/unknown

648 (56.5%)

498 (43.5%)

 Married

628 (51.6%)

588 (48.4%)

Urban/rural code

 Big metro

686 (52.2%)

628 (47.8%)

 Metro

362 (53.7%)

312 (46.3%)

 Urban

80 (58.8%)

56 (41.2%)

 Less urban/rural

148 (62.2%)

90 (37.8%)

Census tract poverty indicator

 0 to < 5%

296 (50.9%)

285 (49.1%)

 5% to < 10%

305 (49.9%)

306 (50.1%)

 10% to < 20%

365 (55.5%)

293 (44.5%)

 20% to 100%

309 (60.5%)

202 (39.5%)

Medicaid dual-eligible

 No

939 (52.0%)

866 (48.0%)

 Yes

337 (60.5%)

220 (39.5%)

Charlson score

 0

327 (49.7%)

331 (50.3%)

 1

422 (54.1%)

358 (45.9%)

 2

191 (52.8%)

171 (47.2%)

  ≥ 3

336 (59.8%)

226 (40.2%)

Radiation

 No

634 (54.5%)

529 (45.5%)

 Yes

642 (53.5%)

557 (46.4%)